Olema reports Q3 2026 results, reiterates early-2027 OPERA-01 data timeline
Olema said it remains on track to report top-line results from its pivotal Phase 3 OPERA-01 trial of palazestrant in the first quarter of 2027, while enrollment continues in a second pivotal trial and an early-stage.
FDA, SEC filing (2)